The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Segment loss | -13,646 | - |
| Depreciation and amortization | 1,553 | - |
| Stock-based compensation expense | 6,911 | - |
| Change in contingent consideration | 0 | - |
| Impairment | 0 | - |
| Interest income | 3,529 | - |
| Other income (expense), net | 315 | - |
| Income tax expense | 1,336 | - |
| Net loss | -19,602 | -20,319 |
| Depreciation of property and equipment | 905 | 1,866 |
| Amortization of intangible assets | 648 | 3,223 |
| Stock-based compensation expense | 6,911 | 12,273 |
| Amortization of operating lease right-of-use assets | 1,031 | 1,430 |
| Impairment of acquired ipr&d (note 6) | 0 | 0 |
| Deferred income tax recovery | 170 | 295 |
| Change in fair value of contingent consideration liability | 0 | 0 |
| Unrealized foreign exchange loss (gain) | 451 | -678 |
| Accounts receivable | 26,721 | -53,208 |
| Prepaid expenses and other current assets | -3,267 | -8,362 |
| Accounts payable and accrued liabilities | 3,341 | -28,324 |
| Operating lease liabilities | -872 | -1,632 |
| Deferred revenue | -614 | -21,777 |
| Income taxes payable | 915 | -27 |
| Net cash provided used in operating activities | -31,412 | 8,666 |
| Issuance of common stock on exercise of stock options | 7,923 | 2,156 |
| Issuance of common stock through employee stock purchase plan | 881 | 544 |
| Purchases of common stock for retirement (note 8b) | 16,216 | - |
| Private placement for issuance of common stock (note 8c) | 4,988 | - |
| Deferred financing costs | 28 | 65 |
| Net cash provided by (used in) financing activities | -2,452 | 2,635 |
| Purchases of marketable securities | 35,054 | 104,179 |
| Proceeds from marketable securities | 35,832 | 126,328 |
| Acquisition of property and equipment | 410 | 530 |
| Acquisition of intangible assets | 0 | 692 |
| Net cash provided by investing activities | 368 | 20,927 |
| Effect of exchange rate changes on cash and cash equivalents | 77 | -78 |
| Net change in cash and cash equivalents | -33,419 | 32,150 |
| Cash and cash equivalents at beginning of period | 66,103 | - |
| Cash and cash equivalents at end of period | 64,834 | - |
Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME)